CASI Pharmaceuticals (CASI.F) Stock Analysis & Winston Score

CASI Pharmaceuticals is a drug company focused on bringing cancer treatments and other medicines to patients in China. Its main products include EVOMELA, a drug used before bone marrow transplants, and it also sells a portfolio of hematology and oncology medicines. The company works with hospitals and cancer treatment centers as its primary customers. CASI makes money by selling its approved drugs directly in China, and it also earns revenue through licensing deals and partnerships with other pharmaceutical companies. The company operates almost entirely in China, making it a small, niche player in one of the world's largest and fastest-growing pharmaceutical markets. Its main growth driver is expanding its product pipeline and gaining approvals for new drugs in China, but its biggest risk is heavy dependence on a single country, which exposes it to regulatory changes, pricing pressure from China's national drug reimbursement negotiations, and intense local competition.